

Dr. Les Kaplan's Biography

Les Kaplan, Ph.D. has served on Nicox's board of directors since October 2014. His term will expire at the end of the annual general meeting called to approve the financial statements of the fiscal year ended December 31, 2021. He is chairman of the science and technology committee, member of the corporate governance committee and of the social, societal and environmental responsibility (CSR) committee. The renewal of his term of office for four years will be submitted to Nicox's ordinary general meeting convened for June 14, 2022. Dr. Kaplan was the executive chairman of Acix Therapeutics, Inc., a pharmaceutical development company acquired by Nicox in October 2014. Dr. Kaplan began his career at Allergan Inc., where he served as president of research and development and led approvals of over 20 major pharmaceutical products and indications. Prior to joining Allergan, Dr. Kaplan held research positions at the Upjohn Company and at the University of California, Los Angeles, and instructed in chemistry at both Temple University, Philadelphia and University of California, Los Angeles. Dr. Kaplan previously served as a member of the board of directors of Allergan, of Altheos (U.S.), Acadia Pharmaceuticals Inc.(U.S.) and Neurotech Inc.(U.S.).

Dr. Kaplan received a B.S. in chemistry from the University of Illinois, Urbana Champaign and a Ph.D. in organic chemistry from the University of California, Los Angeles. He is 71 years old. He holds 82,034 Nicox shares.